

# Facts & Figures




**16**

state-of-the-art production facilities

in **14** countries, including all major pharma hubs

## Global Footprint



**€957** million revenues

(+12% at constant currencies)

**€258** million EBITDA

Margin: 26.9%



**>1,000**

patents and designs developed

**>120**

employees

active in R&D collaborating with an exclusive network of partners

On average, **more than 25,000 injections per minute** are provided to patients worldwide through a SCHOTT Pharma product.

**~13**

billion products delivered every year

Glass syringes



Polymer syringes




Cartridges



Vials



Ampoules



**Broad ready-to-use portfolio**

# Market & Customers

The top 30 global pharma companies use SCHOTT Pharma's solutions.

>1,800

customers worldwide



Big pharma innovators



Leading CDMOs



Biotechs & start-ups

## Growth opportunities from structural trends

### mRNA therapies

New drug categories require deep-cold storage (-100°C)



SCHOTT Pharma currently offers the only prefillable syringes for these applications<sup>1</sup>

### GLP-1 drugs

Increasing demand to treat type-2 diabetes, obesity



SCHOTT Pharma has long-term contracts with the leading GLP-1 players

### Homecare solutions

Enabling patients to inject drugs at home, reducing healthcare cost



SCHOTT Pharma contributes to fully integrated systems from device manufacturers

### Manufacturing transformation

Smaller patient populations require more flexible filling lines



SCHOTT Pharma offers pre-sterilized, ready-to-use products for utmost flexibility

### Subcutaneous injections

Subcutaneous large-volume injections of biologics are more patient-friendly



SCHOTT Pharma's cartridges and syringes feature precise geometry to ensure accurate dosing and reducing injection forces

### Antibody-drug conjugates (ADCs)

Innovative ADC therapies need to be lyophilized to ensure drug efficacy



SCHOTT Pharma offers specialty vials that fully eliminate fogging thanks to a hydrophobic inner coating

<sup>1</sup>No competitor disclosed a product with mentioned specifications so far

# ESG Responsibility




↓ **60%**  
reduced CO<sub>2</sub> emissions since 2019<sup>1</sup>

Already using  
→ **100%**  
green electricity worldwide

  
**~4,700**  
employees from over  
**60**  
nationalities

**>40% female employees**  
  
~24%  
of leadership positions held by women



### Executive Board

**Andreas Reisse, CEO**

- Over 35 years of experience
- Heading SCHOTT's pharma business since 2010
- Previously headed SCHOTT's Tubing business unit
- Master Degree in Industrial Engineering

**Dr. Almuth Steinkühler, CFO**

- Over 15 years of experience
- Leading the finance organization since 2022
- Previous management roles with thyssenkrupp and Continental
- PhD in Management Accounting

<sup>1</sup> Scope 1 & 2; Defined as corporate CO2 footprint of SCHOTT Pharma divided by number of good pieces sold (as of FY 2022)

# SCHOTT Pharma's Governance

**KGaA** (Kommanditgesellschaft auf Aktien) is a listed partnership limited by shares with three **corporate bodies**:

- **general partner** (Komplementär)
- **supervisory board** (Aufsichtsrat)
- **general shareholders' meeting** (Hauptversammlung)

As a **popular legal form** for companies originating from families or foundations, there are many **established KGaA** in Germany.

## Supervisory Board

### Shareholder representatives



Chairman  
Peter Goldschmidt,  
CEO Stada AG



Deputy Chairman  
Dr. Wolfgang Wienand,  
CEO Siegfried Holding AG



Eva Kienle,  
CFO  
KWS Saat SE & Co. KGaA



Ann-Kristin Erkens,  
CFO  
SIG Group AG

### Employee representatives



Mario Just,  
SCHOTT Pharma



Christine Wening,  
SCHOTT Pharma

## Press contact

**Lea Kaiser**

[lea.kaiser@schott.com](mailto:lea.kaiser@schott.com)

+49 (0) 151/68 91 71 95

**Joana Kornblum**

[joana.kornblum@schott.com](mailto:joana.kornblum@schott.com)

+49 (0) 151/29 22 35 52